Form 4: Corvus Pharma Director Exercises Options, Boosts Holdings

Peter A. Thompson, a Director and 10% owner of Corvus Pharmaceuticals, Inc., exercised multiple stock options to acquire 210,000 shares of common stock.

Summary

• Peter A. Thompson, a Director and 10% owner of Corvus Pharmaceuticals, Inc. (CRVS), executed a series of transactions on January 28, 2026, under a Rule 10b5-1 plan.
• Thompson acquired a total of 210,000 shares of Corvus Pharmaceuticals common stock through the exercise of stock options.
• The acquired shares were obtained at various exercise prices ranging from $0.965 to $15 per share.
• Following these transactions, Thompson directly beneficially owns 210,000 shares of common stock.
• Additionally, 8,609,091 shares are indirectly held by OrbiMed Private Investments V, LP (OPI V), where Thompson is a member of OrbiMed Advisors, the managing member of GP V, which is the general partner of OPI V.
• Thompson disclaims beneficial ownership of the reported securities, except to the extent of his pecuniary interest, due to an agreement to transfer the economic benefit to OrbiMed Advisors and GP V for OPI V.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive signal. The exercise of options by a director and 10% owner, especially under a 10b5-1 plan, suggests a pre-determined confidence in the company's value and future, although it's not a spontaneous 'buy' decision.

Positives

• The exercise of stock options by a director and 10% owner can signal confidence in the company's future prospects, especially when options are exercised at various strike prices.
• The acquisition of 210,000 shares directly increases the insider's direct stake in the company, aligning their interests further with shareholders.

Negatives

• The filing does not contain any negative financial or operational information about Corvus Pharmaceuticals, Inc.

Risks

• The reporting person disclaims beneficial ownership of the securities reported for purposes of Rule 16a-1(a) under the Exchange Act, except to the extent of his pecuniary interest, which could imply a complex ownership structure or limited direct financial exposure for the reporting person despite the transactions.

Future Outlook

The filing indicates pre-planned transactions under a Rule 10b5-1 plan, with the earliest transaction date set for January 28, 2026. This suggests a scheduled increase in insider holdings, reflecting a long-term strategy rather than an immediate market reaction.

Industry Context

StockSavvy.ai notes that insider transactions, particularly option exercises by a director and significant owner, are common in the biotechnology and pharmaceutical sectors. Such activities often reflect the individual's long-term view on the company's pipeline and market potential, rather than short-term operational news. The involvement of OrbiMed, a prominent healthcare investment firm, further contextualizes these holdings within specialized life sciences investment strategies.

Related Party Transactions

• Peter A. Thompson is obligated to transfer any securities issued under stock options or their economic benefit to OrbiMed Advisors LLC and OrbiMed Capital GP V LLC, which will then provide them to OrbiMed Private Investments V, LP (OPI V).
• Thompson disclaims beneficial ownership of the reported securities, except for his pecuniary interest, due to this arrangement with OrbiMed entities.

Stakeholder Impact

• Shareholders may view the insider's option exercises as a positive indicator of management's belief in the company's long-term value, potentially boosting investor confidence.
• The complex beneficial ownership structure involving OrbiMed entities highlights the influence of institutional investors on the company's governance and shareholding.

Key Dates

Recommendation

While insider option exercises can be a positive signal of confidence, these are pre-planned transactions under a 10b5-1 plan, not a spontaneous market purchase. The complex beneficial ownership structure also warrants a cautious 'hold' recommendation, as the direct pecuniary interest of the reporting person is disclaimed in favor of institutional entities. Investors should consider broader company fundamentals and market conditions rather than solely relying on this insider transaction.

Keywords

Corvus Pharmaceuticals, CRVS, Peter A. Thompson, Insider Trading, Form 4, Stock Options, Equity Acquisition, 10b5-1 Plan, Director Holdings, OrbiMed